VIGL(Delisted)
Vigil Neuroscience·NASDAQ
--
--(--)
VIGL Profile
Vigil Neuroscience, Inc.
A microglia-focused therapeutics company focused on developing treatments for neurodegenerative diseases
100 Forge Road, Suite 700, Watertown, MA 02472
--
Vigil Neuroscience, Inc., was incorporated under the laws of the State of Delaware on June 22, 2020. The company is a clinical-stage biotechnology company dedicated to improving the lives of patients, caregivers and families with rare and common neurodegenerative diseases by developing disease-improving therapies to restore microglia vigilance. The company's first therapeutic drug candidates are designed to activate trigger receptor (TREM 2) expressed on marrow-like cells 2, a key microglia receptor protein that mediates responses to environmental signals to maintain brain health, and its dysfunction is associated with neurodegeneration. The company has two major projects aimed at TREM 2. The Company's lead product candidate, VGL101, is a fully human monoclonal antibody (mAb) TREM 2 agonist (or activator), currently under study in a Phase 2 proof-of-concept trial for a rare and fatal neurodegenerative disease — adult leukoencephalopathy patients with axonal spheres and pigment glial cells (ALSP). The company's second project focuses on small molecule TREM 2 agonists and is currently in investigational new drug (IND) licensing studies.
